Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (10): 967-968.DOI: 10.3969/j.issn.1673-8640.2018.10.024
Received:2017-09-17
Online:2018-10-30
Published:2018-10-23
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.10.024
| 测定次序 | TT （s） | 2∶1 混合试验（s） | 参考区间（s） |
|---|---|---|---|
| 初次检测 | 不凝固 | 66.6 | 14.0~21.0 |
| 第1次复检 | 135.4 | 14.0~21.0 | |
| 第2次复检 | 132.1 | 14.0~21.0 | |
| 第3次复检 | 不凝固 | 14.0~21.0 |
| 测定次序 | TT （s） | 2∶1 混合试验（s） | 参考区间（s） |
|---|---|---|---|
| 初次检测 | 不凝固 | 66.6 | 14.0~21.0 |
| 第1次复检 | 135.4 | 14.0~21.0 | |
| 第2次复检 | 132.1 | 14.0~21.0 | |
| 第3次复检 | 不凝固 | 14.0~21.0 |
| [1] | WOJTUKIEWICZ M Z,HEMPEL D,SIERKO E,et al.Thrombin-unique coagulation system protein with multifacted impacts on cancer and metastasis[J]. Cancer Metastasis Rev,2016,35(2):213-233. |
| [2] | BAGLIN T,KEELING D,KITCHEN S,et al.Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban:guidance from the British Committee for Standards in Haematology[J]. Br J Haematol,2012,159( 4):427-429. |
| [3] | DALE B J,GINSBERG J S,JOHNSTON M,et al.Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents[J]. J Thromb Haemost,2014,12(11):1810-1815. |
| [4] | BOONEN K,SCHMITZ E,ROZESTRATEN F,et al.Real life dabigatran and metabolite concentrations,focused on inter-patient variability and assay differences in patients with atrial fibrillation[J]. Clin Chem Lab Med,2017,55(12):2002-2009. |
| [5] | 中华心血管病杂志编辑委员会血栓栓塞防治循证工作组. 达比加群酯用于非瓣膜病心房颤动患者卒中预防的临床应用建议[J]. 中华心血管病杂志,2014,42(3):188-192. |
| [6] | HAPGOOD G,BUTLER J,MALAN E,et al.The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples[J]. Thromb Haemost,2013,110(2):308-315. |
| [7] | SHIMOMURA D,NAKAGAWA Y,KONDO H,et al.Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation[J]. J Arrhythm,2015,31(4):183-188. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
